Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

57
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

54
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
54
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
Human Genetics01:28

Human Genetics

1.7K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.7K
Bipolar Disorder01:30

Bipolar Disorder

1.2K
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain-first versus body-first Parkinson's disease: Differential findings on pupillary, brainstem and vagus sonography.

Journal of neurology·2026
Same author

Agreement between relatives of Parkinson's patients and clinical observer in home diary assessments.

Journal of Parkinson's disease·2026
Same author

Altered light-dark phase-dependent behavioral responses and suprachiasmatic nucleus pathology in an α-synuclein rat model of Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Deep brain stimulation in alpha-synuclein models of Parkinson's disease: Bridging the translational gap.

Journal of Parkinson's disease·2026
Same author

Non-motor fluctuation patterns in dyskinetic patients with advanced Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study.

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Feb 26, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.4K

Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues.

Joseph Classen1, Jiri Koschel2, Christian Oehlwein3

  • 1Department of Neurology, University of Leipzig, 04103, Leipzig, Germany. joseph.classen@medizin.uni-leipzig.de.

Journal of Neural Transmission (Vienna, Austria : 1996)
|July 14, 2017
PubMed
Summary

Parkinson's disease (PD) patients experience non-motor fluctuations (NMFs) due to levodopa therapy. Current guidelines lack recommendations for managing these debilitating NMFs, highlighting a critical gap in PD care.

Keywords:
Non-motor assessmentNon-motor fluctuationsNon-motor symptomsParkinson’s diseasePathophysiology

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

54.6K

Related Experiment Videos

Last Updated: Feb 26, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.4K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

54.6K

Area of Science:

  • Neurology
  • Neuroscience
  • Movement Disorders

Background:

  • Parkinson's disease (PD) involves progressive motor and non-motor symptoms impacting quality of life.
  • Advanced PD presents motor complications from levodopa, like fluctuations and dyskinesias.
  • Non-motor symptoms can precede motor deficits and significantly impair patients.

Purpose of the Study:

  • To review the clinical phenomenology and pathophysiology of non-motor fluctuations (NMFs) in Parkinson's disease.
  • To identify gaps in current Parkinson's disease management guidelines regarding NMFs.
  • To outline future research directions for understanding and managing NMFs.

Main Methods:

  • Literature review and synthesis of existing research on non-motor symptoms and levodopa therapy in Parkinson's disease.
  • Analysis of clinical phenomenology and proposed pathophysiological mechanisms of NMFs.
  • Examination of current national treatment guidelines for Parkinson's disease.

Main Results:

  • Non-motor symptoms, including psychiatric issues, fatigue, and pain, exhibit fluctuations after chronic levodopa therapy, termed NMFs.
  • NMFs represent a significant challenge in advanced Parkinson's disease, often overlooked in current treatment protocols.
  • Existing national guidelines for Parkinson's disease management do not specifically address NMFs or provide management recommendations.

Conclusions:

  • Non-motor fluctuations (NMFs) are a recognized phenomenon in Parkinson's disease, influenced by levodopa therapy.
  • There is a pressing need to incorporate NMF management into clinical practice and guidelines for Parkinson's disease.
  • Further research is essential to elucidate the pathophysiology and develop effective therapeutic strategies for NMFs.